Efficacy and Safety of Immune Checkpoint Inhibitors (ICI) in Resectable Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis

被引：0
|
作者：
Xiao, T. [1 ]
Verma, S. [1 ]
Boldt, G. [1 ]
Rajeh, A. [1 ]
Breadner, D. [2 ]
Raphael, J. [3 ]
机构：
[1] Western Univ, London, ON, Canada
[2] LRCP, London, ON, Canada
[3] Western Univ, London Hlth Sci Ctr, London, ON, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
103
引用
收藏
页码：E6 / E6
页数：1
相关论文
共 50 条
  • [41] Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis
    Lin, Lanlan
    Yang, Fan
    Lin, Guofu
    Chen, Xiangqi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (02): : 210 - 218
  • [42] Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis
    Mei, T.
    Zhou, Q.
    Gong, Y.
    CLINICAL ONCOLOGY, 2024, 36 (02) : 107 - 118
  • [43] Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
    Li Yan
    Liang Xueyan
    Li Huijuan
    Chen Xiaoyu
    中华医学杂志英文版, 2023, 136 (18)
  • [44] Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis
    Cui, Ran
    Li, Yun
    Yu, Xinlin
    Wei, Chun
    Jiang, Ou
    PLOS ONE, 2024, 19 (06):
  • [45] Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Chen, Xiaoyu
    CHINESE MEDICAL JOURNAL, 2023, 136 (18) : 2156 - 2165
  • [46] Efficacy and safety of Toliparibumab for the treatment of non-small cell lung cancer: a systematic review and meta-analysis
    Liu, Yihao
    Yang, Liangyu
    Duan, Zhixuan
    Cheng, Qian
    Liu, Minghui
    Zhang, HongBing
    Zhao, HongLin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] Efficacy and safety of neoadjuvant immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis
    Xu, Ke
    Ni, Juan
    Wu, Xiaodi
    Xie, Jingyuan
    Chen, Mo
    Zhang, Fang
    Liu, Hongbing
    Zhan, Ping
    Lv, Tangfeng
    Song, Yong
    AME MEDICAL JOURNAL, 2022, 7
  • [48] Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis
    Olivares-Hernandez, Alejandro
    Roldan-Ruiz, Jonnathan
    Miramontes-Gonzalez, Jose Pablo
    Toribio-Garcia, Irene
    Garcia-Hernandez, Juan Luis
    Posado-Dominguez, Luis
    Bellido-Hernandez, Lorena
    Cruz-Hernandez, Juan Jesus
    Fonseca-Sanchez, Emilio
    del Barco-Morillo, Edel
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (06)
  • [49] Prediction accuracy of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis
    Zhuang, Wei
    Zhao, Jie
    Sun, Boyang
    Bai, Hua
    Wang, Zhijie
    Zhong, Jia
    Wan, Rui
    Liu, Lihui
    Duan, Jianchun
    Wang, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
    Suay, Guillermo
    Garcia-Canaveras, Juan-Carlos
    Aparisi, Francisco
    Lahoz, Agustin
    Juan-Vidal, Oscar
    CANCERS, 2023, 15 (18)
12345